Currently, Pembrolizumab is used in HR (hormone receptor)-negative and HER2-negative breast cancers as a peri-operative therapy in association with neoadjuvant chemotherapy and as an adjuvant systemic therapy, in particular cases, with notable results [85,86,87,88]. This evidence concerns the gene ERBB2 and breast cancer.